Cempra to Present Data on Solithromycin at ECCMID

CHAPEL HILL, N.C., April 04, 2016 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 26^th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The meeting will take place in Amsterdam, Netherlands from Saturday, April 9 to Tuesday, April 12, 2016.

Poster presentations for solithromycin at ECCMID include the following (times are CEST):

• Comparison of solithromycin MICs generated by BSAC and CLSI methods, Hardy Dwight – Paper Poster Area, poster #0817, April 10 (1:30-2:30 p.m.). An abstract for the presentation is available here - ECCMID meeting website.
• In-vitro activity of solithromycin against anaerobic bacteria in the normal intestinal microbiota, Andrej Weintraub – Paper Poster Area, poster #1335, April 11 (1:30-2:30 p.m.). An abstract for the presentation is available here - ECCMID meeting website.
• Ecological effect of solithromycin on the normal human intestinal microbiota, Mamun-Ur Rashid – Paper Poster Area, poster #1336, April 11 (1:30-2:30 p.m.). An abstract for the presentation is available here - ECCMID meeting website.
• Microbial characterization using multiple diagnostic methods in the first oral phase 3 community-acquired bacterial pneumonia (CABP) trial with solithromycin, Kara Keedy – Paper Poster Area, poster #1337, April 11 (1:30-2:30 p.m.). An abstract for the presentation is available here - ECCMID meeting website.
  
• SOLITAIRE-IV: a phase 3 IV to oral trial evaluating solithromycin in adults with community-acquired bacterial pneumonia, Brian Jamieson – Paper Poster Area, poster #1338, April 11 (1:30-2:30 p.m.). An abstract for the presentation is available here - ECCMID meeting website.
  
  

About Cempra, Inc.

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.

CONTACTS:
Investor Contact:
Robert H. Uhl
Westwicke Partners, LLC
(858) 356-5932
[email protected]

Media Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]